# Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms

Page: https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms
Text version: https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms.md
Podcast: [HCPLive Podcasts](https://stenobird.com/podcast/hcplive-podcasts-19526)
Published: 2026-05-28T19:01:00+00:00
Episode link: https://audioboom.com/posts/8909059
Audio file: https://audioboom.com/posts/8909059.mp3?modified=1779994664&sid=5004077&source=rss
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms
Duration seconds: 1500

## Resource

In this episode of Joint Ventures , hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.